Molecular Oncology
Volume 4, Issue 4 , Pages 335-346 , August 2010

High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V

  • Robert Fritsche-Polanz

      Affiliations

    • Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Austria
    • Institute of Laboratory Diagnostics, Kaiser Franz-Joseph Spital, Vienna, Austria
    • ,
  • Marika Fritz

      Affiliations

    • Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Austria
    • ,
  • Andrea Huber

      Affiliations

    • Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Austria
    • ,
  • Karl Sotlar

      Affiliations

    • Institute of Pathology, University of Munich, Germany
    • ,
  • Wolfgang R. Sperr

      Affiliations

    • Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria
    • ,
  • Christine Mannhalter

      Affiliations

    • Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Austria
    • ,
  • Manuela Födinger

      Affiliations

    • Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Austria
    • Institute of Laboratory Diagnostics, Kaiser Franz-Joseph Spital, Vienna, Austria
    • ,
  • Peter Valent

      Affiliations

    • Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria
    • Ludwig-Boltzmann Cluster Oncology, Vienna, Austria
    • Corresponding Author InformationCorresponding author at: Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. Tel.: +43 1 40400 6085; fax: +43 1 40400 4030.

Received 4 February 2010 ,Revised 17 April 2010 ,Accepted 19 April 2010.

References 

  1. Akin C, Brockow K, D’Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated forms of c-kit. Exp. Hematol. 2003;31:686–692
  2. Akin C, Metcalfe DD. Systemic mastocytosis. Annu. Rev. Med. 2004;55:419–432
  3. Ashman LK, Cambareri AC, To LB, Levinsky RJ, Juttner CA. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood. 1991;78:30–37
  4. Ashman LK, Ferrao P, Cole SR, Cambareri AC. Effects of mutant c-kit in early myeloid cells. Leuk. Lymphoma. 2000;37:233–243
  5. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann. Intern. Med. 1985;103:620–625
  6. Bernd HW, Sotlar K, Lorenzen J, et al. Acute myeloid leukaemia with t(8;21) associated with “occult” mastocytosis. Report of an unusual case and review of the literature. J. Clin. Pathol. 2004;57:324–328
  7. Broudy VC, Smith FO, Lin N, Zsebo KM, Egrie J, Bernstein ID. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood. 1992;80:60–67
  8. Brunning RD, Vardiman J, Matutes E, et al. Acute myeloid leukemia. World Health Organization (WHO) classification of tumours. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. Pathology & Genetics. first ed.. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001;p. 77–105
  9. Bühring HJ, Ullrich A, Schaudt K, Muller CA, Busch FW. The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells. Leukemia. 1991;5:854–860
  10. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk. Res. 1988;12:345–355
  11. Cairoli R, Beghini A, Morello E, et al. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases. Leuk. Res. 2005;29:397–400
  12. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107:3463–3468
  13. Cammenga J, Horn S, Bergholz U, et al. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood. 2005;106:3958–3961
  14. Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br. J. Haematol. 2003;121:775–777
  15. Escribano L, Orfao A, Diaz-Agustin B, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91:2731–2736
  16. Escribano L, Diaz-Agustin B, Lopez A, et al. Spanish Network on Mastocytosis (REMA). Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B. Clin. Cytom. 2004;58:1–8
  17. Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368:1894–1907
  18. Feger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int. Arch. Allergy Immunol. 2002;127:110–114
  19. Fritsche-Polanz R, Jordan JH, Feix A, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br. J. Haematol. 2001;113:357–364
  20. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J. Clin. Invest. 1993;91:1736–1744
  21. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108:2366–2372
  22. Goemans BF, Zwaan CM, Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia. 2005;19:1536–1542
  23. Horny HP, Ruck M, Wehrmann M, Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br. J. Haematol. 1990;76:186–193
  24. Horny HP, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am. J. Surg. Pathol. 1998;22:1132–1140
  25. Kirshenbaum AS, Goff JP, Kessler SW, Mican JM, Zsebo KM, Metcalfe DD. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J. Immunol. 1992;148:772–777
  26. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnic HR. Hematologic manifestation of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am. J. Med. 1991;91:612–624
  27. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 1996;12:312–314
  28. Longley BJ, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis. Proc. Natl. Acad. Sci. (USA). 1999;96:1609–1614
  29. Mayerhofer M, Gleixner KV, Hoelbl A, et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J. Immunol. 2008;180:5466–5476
  30. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J. Invest. Dermatol. 1991;96:2S-4S
  31. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18:115–136
  32. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. (USA). 1995;91:10560–10564
  33. Nanri T, Matsuno N, Kawakita T, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia. 2005;19:1361–1366
  34. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791–1799
  35. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N. Engl. J. Med. 1987;316:1622–1626
  36. Schwartz LB, Sakai K, Bradford TR, et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J. Clin. Invest. 1995;96:2702–2710
  37. Shimada A, Taki T, Tabuchi K, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood. 2006;107:1806–1809
  38. Sillaber C, Strobl H, Bevec D, et al. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J. Immunol. 1991;147:4224–4228
  39. Simmons PJ, Aylett GW, Niutta S, To LB, Juttner CA, Ashman LK. c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture. Exp. Hematol. 1994;22:157–165
  40. Sotlar K, Marafioti T, Griesser H, et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol. Pathol. 2000;53:188–193
  41. Sotlar K, Fridrich C, Mall A, et al. Detection of c-kit point mutation Asp-816 → Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk. Res. 2002;26:979–984
  42. Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am. J. Pathol. 2003;162:737–746
  43. Sperr WR, Walchshofer S, Horny HP, et al. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br. J. Haematol. 1998;103:740–749
  44. Sperr WR, Horny HP, Lechner K, Valent P. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk. Lymphoma. 2000;37:473–486
  45. Sperr WR, Jordan JH, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood. 2001;98:2200–2209
  46. Sperr WR, Escribano L, Jordan JH, et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk. Res. 2001;25:529–536
  47. Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int. Arch. Allergy Immunol. 2002;127:140–142
  48. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer. 2003;3:650–665
  49. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG. Significance of systemic mast cell disease with associated hematologic disorders. Cancer. 1988;62:965–972
  50. Tsai M, Shih LS, Newlands GF, et al. The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomical distribution, histochemistry, and protease phenotype. J. Exp. Med. 1991;174:125–131
  51. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res. 2001;25:603–625
  52. Valent P, Horny HP, Li CY, et al. Mastocytosis (Mast cell disease). World Health Organization (WHO) classification of tumours. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. vol. 1:Lyon: IARC Press; 2001;p. 291–302
  53. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur. J. Clin. Invest. 2007;37:435–453
  54. Valent P, Spanblöchl E, Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood. 1992;80:2237–2245
  55. Valent P. The riddle of the mast cell: kit(CD117)-ligand as the missing link?. Immunol. Today. 1994;15:111–114
  56. Valent P. Biology, classification and treatment of human mastocytosis. Wien. Klin. Wochenschr. 1996;108:385–397
  57. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br. J. Haematol. 2003;122:695–717
  58. Zsebo KM, Wypych J, McNiece IK, et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell. 1990;63:195–201

☆ Supported by: Fonds zur Förderung der Wissenschaftlichen Forschung in Österreich (FWF), grant #P21173-B13.

PII: S1574-7891(10)00030-X

doi: 10.1016/j.molonc.2010.04.008

Molecular Oncology
Volume 4, Issue 4 , Pages 335-346 , August 2010

Article Tools

* Image Usage & Resolution